RNXT8:30 AMRenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancerrenovorx.com
RNXT8:30 AMRenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rdEnrollment • Phase 3Enrollment completion Tue, Jun 30, 2026renovorx.com
RNXT8:30 AMRenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancerrenovorx.com
RNXT8:30 AMRenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual MeetingPresentation / Abstract • Phase 3ASCO abstract release Thu, May 21, 2026, 5:00 PM ETGrenovorx.com
RNXT8:30 AMRenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20thEnrollment • Phase 3Enrollment completion Tue, Jun 30, 2026renovorx.com
RNXT4:05 PMRenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-QuarterEnrollment • Phase 3Enrollment completion Tue, Jun 30, 2026renovorx.com
RNXT8:30 AMRenovoRx to Host First Quarter 2026 Financial Results and Business Highlights Conference Call on May 14th at 4:30 pm ETrenovorx.com
RNXT8:30 AMRenovoRx Announces Pharmacokinetic and Pharmacodynamic Data Abstract Supporting the TAMP™ Therapy Platform Accepted for Presentation at the 2026 ASCO Annual MeetingPresentation / Abstract • Phase 3renovorx.com
RNXT8:30 AMClinical Data Supporting Targeted Chemotherapeutic Delivery via RenovoRx’s TAMP™ Therapy Platform Presented at 2026 SIR Annual Scientific MeetingPresentation / Abstractrenovorx.com